Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with IPF

被引：0
|
作者：
Karampitsakos, T. [1 ]
Dimeas, I [2 ]
Tsiri, P. [1 ]
Sotiropoulou, V [1 ]
Tomos, I [3 ]
Papanikolaou, I [4 ]
Katsaras, M. [1 ]
Kirgou, P. [2 ]
Daniil, Z. [2 ]
Gourgoulianis, K. [2 ]
Papalexatos, D. [1 ]
Sampsonas, F. [1 ]
Manali, E. [3 ]
Papiris, S. [3 ]
Bouros, D. [5 ]
Tzouvelekis, A. [1 ]
Papaioannoui, o [1 ]
机构：
[1] Univ Hosp Patras, Dept Resp Med, Patras, Greece
[2] Univ Thessaly, Med Sch, Dept Resp Med, Larisa, Greece
[3] Natl & Kapodistrian Univ Athens, ATTIKON Univ Hosp, Athens Med Sch, Pulm Med Dept 2, Athens, Greece
[4] Corfu Gen Hosp, Resp Med Dept, Corfu, Greece
[5] Natl & Kapodistrian Univ Athens, Hosp Thorac Dis, Acad Dept Pneumonol 1, Med Sch,SOTIRIA, Athens, Greece
来源：
EUROPEAN RESPIRATORY JOURNAL | 2022年 / 60卷
关键词：
D O I：
10.1183/13993003.congress-2022.972
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
972
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
    Karampitsakos, Theodoros
    Papaioannou, Ourania
    Dimeas, Ilias
    Tsiri, Panagiota
    Sotiropoulou, Vasilina
    Tomos, Ioannis
    Papanikolaou, Ilias C.
    Katsaras, Matthaios
    Kirgou, Paraskevi
    Daniil, Zoe
    Gourgoulianis, Konstantinos I.
    Sampsonas, Fotios
    Manali, Effrosyni
    Papiris, Spyridon
    Bouros, Demosthenes
    Tzouvelekis, Argyris
    ERJ OPEN RESEARCH, 2022, 8 (02)
  • [2] Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
    Payne, Rebecca P.
    Longet, Stephanie
    Austin, James A.
    Skelly, Donal T.
    Dejnirattisai, Wanwisa
    Adele, Sandra
    Meardon, Naomi
    Faustini, Sian
    Al-Taei, Saly
    Moore, Shona C.
    Tipton, Tom
    Hering, Luisa M.
    Angyal, Adrienn
    Brown, Rebecca
    Nicols, Alexander R.
    Gillson, Natalie
    Dobson, Susan L.
    Amini, Ali
    Supasa, Piyada
    Cross, Andrew
    Bridges-Webb, Alice
    Reyes, Laura Silva
    Linder, Aline
    Sandhar, Gurjinder
    Kilby, Jonathan A.
    Tyerman, Jessica K.
    Altmann, Thomas
    Hornsby, Hailey
    Whitham, Rachel
    Phillips, Eloise
    Malone, Tom
    Hargreaves, Alexander
    Shields, Adrian
    Saei, Ayoub
    Foulkes, Sarah
    Stafford, Lizzie
    Johnson, Sile
    Wootton, Daniel G.
    Conlon, Christopher P.
    Jeffery, Katie
    Matthews, Philippa C.
    Frater, John
    Deeks, Alexandra S.
    Pollard, Andrew J.
    Brown, Anthony
    Rowland-Jones, Sarah L.
    Mongkolsapaya, Juthathip
    Barnes, Eleanor
    Hopkins, Susan
    Hall, Victoria
    CELL, 2021, 184 (23) : 5699 - +
  • [3] Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
    Ligumsky, Hagai
    Dor, Herut
    Etan, Tal
    Golomb, Inbal
    Nikolaevski-Berlin, Alla
    Greenberg, Inbal
    Halperin, Tamar
    Angel, Yoel
    Henig, Oryan
    Spitzer, Avishay
    Slobodkin, Marina
    Wolf, Ido
    LANCET ONCOLOGY, 2022, 23 (02): : 193 - 195
  • [4] Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
    Naruse, Hiroyuki
    Ito, Hiroyasu
    Izawa, Hideo
    Sarai, Masayoshi
    Ishii, Junnichi
    Sakaguchi, Eirin
    Murakami, Reiko
    Ando, Tatsuya
    Fujigaki, Hidetsugu
    Saito, Kuniaki
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
  • [5] Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients
    Ben Khlil, Ahmed Amine
    Zamali, Imen
    Belloumi, Dorra
    Gdoura, Mariem
    Kharroubi, Ghassen
    Marzouki, Soumaya
    Dachraoui, Rym
    Ben Yaiche, Insaf
    Bchiri, Soumaya
    Hamdi, Walid
    Gharbi, Manel
    Ben Hmid, Ahlem
    Samoud, Samar
    Galai, Yousr
    Torjmane, Lamia
    Ladeb, Saloua
    Bettaieb, Jihene
    Triki, Henda
    Ben Abdeljelil, Nour
    Ben Othman, Tarek
    Ben Ahmed, Melika
    VACCINES, 2024, 12 (02)
  • [6] BNT162b2 mRNA vaccine in transfusion dependent thalassemia patients
    Daungsupawong, Hinpetch
    Wiwanitkit, Viroj
    TRANSFUSION MEDICINE, 2024, 34 (04) : 329 - 329
  • [7] Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers
    Rojkovich, Bernadette
    Nemeth, Dora
    Torok, Eszter
    Szabo, Bernadette
    Pinter, Agnes
    Juhasz, Istvan
    Weidl, Marton
    Lanyi, Eva
    Pavel-Szecsko, Judit
    Lazar, Imre
    Perduk, Andras
    Reiter, Jozsef
    Nagy, Gyorgy
    Nagy, Erzsebet
    Geher, Pal
    ORVOSI HETILAP, 2021, 162 (39) : 1551 - 1557
  • [8] Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study
    Itzhaki Ben Zadok, Osnat
    Shaul, Aviv A.
    Ben-Avraham, Binyamin
    Yaari, Vicky
    Ben Zvi, Haim
    Shostak, Yael
    Pertzov, Barak
    Eliakim-Raz, Noa
    Abed, Galia
    Abuhazira, Miriam
    Barac, Yaron D.
    Mats, Israel
    Kramer, Mordechai R.
    Aravot, Dan
    Kornowski, Ran
    Ben-Gal, Tuvia
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (09) : 1555 - 1559
  • [9] Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients
    Basson, Yael Pri-Paz
    Tayar-Shifman, Oshrat E.
    Naser, Rawand
    Matalon, Shelly Tartakover
    Kimhi, Oded
    Gepstein, Raz
    Halperin, Tamar
    Ziv-Baran, Tomer
    Ziv, Amit
    Parikh, Roma
    Kivity, Shaye
    Levy, Yair
    CLINICAL RHEUMATOLOGY, 2022, 41 (12) : 3879 - 3885
  • [10] Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy
    Diamantopoulos, Panagiotis T.
    Kontandreopoulou, Christina-Nefeli
    Gkoufa, Aikaterini
    Solomou, Elena
    Anastasopoulou, Amalia
    Palli, Eleni
    Kouzis, Panagiotis
    Bouros, Spyros
    Samarkos, Mihalis
    Magiorkinis, Gkikas
    Gogas, Helen
    CANCERS, 2022, 14 (15)
12345